AbCellera Biologics Inc. (NASDAQ:ABCL) traded at $11.82 at close of the session on Friday, 01/07/22, made a downward move of -2.23% on its previous day’s price.

Looking at the stock we see that its previous close was $12.09 with the day’s price range being $11.50 – $12.59. The company has a trailing 12-month PE ratio of 16.53. In terms of its 52-week price range, ABCL has a high of $55.22 and a low of $11.43. The company’s stock has lost about -21.83% over that past 30 days.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


AbCellera Biologics Inc. has a market cap of $3.40 billion and is expected to release its quarterly earnings report on Mar 28, 2022 – Apr 01, 2022. Estimates by analysts give the company expected earnings per share (EPS) of $0.18, with the EPS growth for the year raised at $0.5 for 2021 and -$0.08 for next year. These figures represent 11.10% and -116.00% growth in EPS for the two years respectively.

Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $120.31 million, with a low of $106.4 million and a high of $142.68 million. The median projection represents growth adding up to -42.10% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $353.06 million, or 51.40% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the ABCL stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 8 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the AbCellera Biologics Inc. (ABCL) stock as a Hold, while 8 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the ABCL stock currently stands at 1.65, and the current price level is -15.67% off its SMA20 and -19.87% from its 50-day simple moving average. The RSI (14) is pointing at 34.29 while the volatility over the past week is 8.90% and jumps to 7.79% over the past one month. The average price target for the stock over the next 12 months is $38.88, with the estimates having a low of $25.00 and a high of $49.00. These price ends are -111.51% and -314.55% off the current price level respectively, although investors could be excited at the prospect of a -238.41% if the ABCL share price touches on the median price of $40.00.

Coming back to AbCellera Biologics Inc. (NASDAQ:ABCL), we note that the average 3-month trading volume was 1.81 million. Current shares outstanding are 278.93 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

The insiders hold 21.00% of the company’s shares while institutions hold 43.60%. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -17.34% down in year-to-date price movement.